Possibility of a new anti-alzheimers disease pharmaceutical composition combining memantine and vitamin d

Drugs and Aging

Volumn 29, Issue 2, 2012, Pages 81-91

  Annweiler, Códric ^a,b   Beauchet, Olivier ^a,b  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ D'ANGERS   (France)

Author keywords

Alzheimers disease; Colecalciferol; Memantine.

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMYLOID BETA PROTEIN[1-42]; CALCITRIOL; CALCIUM CHANNEL L TYPE; CALCIUM ION; CHOLINESTERASE INHIBITOR; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; PLACEBO; TAU PROTEIN; VITAMIN D; VITAMIN D RECEPTOR;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXCITOTOXICITY; HUMAN; LEARNING; MEDICAL RESEARCH; MEMORY; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SYNAPTOSOME; VITAMIN D RESPONSIVE ELEMENT;

ALZHEIMER DISEASE; ANIMALS; DRUG COMBINATIONS; GLUTAMIC ACID; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; VITAMIN D;

EID: 84856296940     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11597550-000000000-00000     Document Type: Article

References (92)

1. Abbott A. Dementia: a problem for our age. Nature 2011; 475 (7355): S2-4
2. Ballard B, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011; 377 (9770): 1019-31
3. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362 (4): 329-44
4. Vellas B, Aisen PS. Early Alzheimer's trials: new developments. J Nutr Health Aging 2010; 14 (4): 293
5. Aisen PS. Pre-dementia Alzheimer's trials: overview. J Nutr Health Aging 2010; 14 (4): 294
6. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD005593
7. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154
8. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-targetdirected ligands to combat neurodegenerative diseases. J Med Chem 2008; 51 (3): 347-72 (Pubitemid 351252260)
9. Ho R, Ortiz D, Shea TB. Amyloid-beta promotes calcium influx and neurodegeneration via stimulation of L voltagesensitive calcium channels rather than NMDA channels in cultured neurons. J Alzheimers Dis 2011; 3 (5): 479-83
10. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamateinduced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15 (4): 961-73
11. Bonfoco E, Krainc D, Ankarcrona M, et al. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995; 92 (16): 7162-6
12. Hardingham GE. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 2009; 37 (Pt 6): 1147-60
13. Pinheiro PS, Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 2008; 9 (6): 423-36
14. McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology (Berl) 1993; 111 (4): 391-401 (Pubitemid 23205661)
15. Moult PR. Neuronal glutamate and GABAA receptor function in health and disease. Biochem Soc Trans 2009; 37 (Pt 6): 1317-22
16. Kauer JA, Malenka RC, Nicoll RA. NMDA application potentiates synaptic transmission in the hippocampus. Nature 1988; 334 (6179): 250-2
17. Walton HS, Dodd PR. Glutamate-glutamine cycling in Alzheimer's disease. Neurochem Int 2007; 50 (7-8): 1052-66 (Pubitemid 46962807)
18. Dong XX, Wang Y, Qin ZH, Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin, 2009;30(4):379-87
19. Gouras GK, TampelliniD, Takahashi RH, et al. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol 2010; 119 (5): 523-41
20. Sokolow S, Luu SH, Vinters HV, et al. P1-240 - glutamatergic (VGLUT1) synapses are not lost in Alzheimer's disease cerebral cortex, but preferentially accumulate amyloid-beta and p-tau pathology [abstract]. Alzheimers Dement 2010; 6: S243
21. Thibault O, Gant JC, Landfield PW. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store. Aging Cell 2007; 6 (3): 307-17 (Pubitemid 46785136)
22. Hirsch EC. Does oxidative stress participate in nerve cell death in Parkinson's disease? Eur Neurol 1993; 33 Suppl. 1: 52-9 (Pubitemid 23235377)
23. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16 (11): 439-44 (Pubitemid 23313517)
24. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18 Suppl. 1: S15-21 (Pubitemid 37150474)
25. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11 (9): 379-87 (Pubitemid 20262465)
26. Portera-Cailliau C, Hedreen JC, Price DL, et al. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995; 15 (5 Pt 2): 3775-87
27. Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer's disease. Drugs 2006; 66 (11): 1515-34 (Pubitemid 44250755)
28. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003; 9 (3): 275-308 (Pubitemid 37254706)
29. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system: too little activation is bad, too much is even worse. Neuropharmacology 2007; 53 (6): 699-723 (Pubitemid 47532143)
30. Herrmann N, Li A, Lanctot K. Memantine in dementia: a review of the current evidence. Expert Opin Pharmacother 2011; 12 (5): 787-800
31. Chen HS, Pellegrini JW, Aggarwal SK, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage againstNMDAreceptormediated neurotoxicity. J Neurosci 1992; 12 (11): 4427-36
32. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 2006; 5 (2): 160-70
33. Annweiler C, Souberbielle JC, Schott AM, et al. Vitamin D in the elderly: 5 points to remember. Geriatr Psychol Neuropsychiatr Vieil 2011; 9 (3): 259-67
34. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357 (3): 266-81
35. Annweiler C, Schott AM, Berrut G, et al. Vitamin D and ageing: neurological issues. Neuropsychobiology 2010; 62 (3): 139-50
36. Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. Curr Opin Clin Nutr Metab Care 2007; 10 (1): 12-9 (Pubitemid 44901128)
37. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002; 13 (3): 100-5 (Pubitemid 36733998)
38. Dickens AP, Lang IA, Langa KM, et al. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs 2011; 25 (8): 629-39
39. Holmøy T, Moen ST, Gundersen TA, et al. 25-Hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult Scler 2009; 15 (11): 1280-5
40. Balabanova S, Richter HP, Antoniadis G, et al. 25-Hydroxyvitamin D, 24, 25-dihydroxyvitamin D and 1,25-dihydroxyvitamin D in human cerebrospinal fluid. 1984; 62 (22): 1086-90
41. Gezen-Ak D, Dursun E, Yilmaze S. The effects of vitamin D receptor silencing on the expression of LVSCC-A1C and LVSCC-AD1D and the release ofNGF in cortical neurons. PLoS One 2011; 6 (3): e17553
42. Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alphahydroxylase in human brain. J Chem Neuroanat 2005; 29 (1): 21-30 (Pubitemid 39602785)
43. Matsuda H. The role of neuroimaging in mild cognitive impairment. Neuropathology 2007; 27 (6): 570-7 (Pubitemid 350045667)
44. Price DL. Aging of the brain and dementia of the Alzheimer type. In: Kandel ER, Schwartz J, Jessel TM, editors. Principals of neural science. New York: McGraw-Hill, 2000: 1149-61
45. Bouillon R, Carmeliet G, Verlinden L, et al. Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev 2008; 29 (6): 726-76
46. Wang TT, Tavera-Mendoza LE, Laperriere D, et al. Large scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005; 19 (11): 2685-95 (Pubitemid 41577243)
47. Lue LF, Kuo YM, Beach T, et al. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 2010; 41 (2-3): 115-28
48. Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21 (1): 98-108 (Pubitemid 32098731)
49. Dursun E, Gezen-Ak D, Yilmaze S. A novel perspective for Alzheimer's disease: vitamin D receptor suppression by amyloid-b induced alterations by vitamin D in cortical neurons. J Alzheimers Dis 2011; 23 (2): 207-19
50. Ibi M, Sawada H, Nakanishi M, et al. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology 2001; 40 (6): 761-71 (Pubitemid 32436453)
51. Berridge MJ. Neuronal calcium signaling. Neuron 1998; 21 (1): 13-26 (Pubitemid 28355688)
52. Demaurex N, Distelhorst C. Cell biology. Apoptosis-the calcium connection. Science 2003; 300 (5616): 65-7 (Pubitemid 36423022)
53. Berridge MJ. Calciumsignal transduction and cellular control mechanisms. Biochim Biophys Acta 2004; 1742 (1-3): 3-7 (Pubitemid 39601763)
54. Coon A, Wallace DR, Mactutus CF, et al. L-type calcium channels in the hippocampus and cerebellum. Neurobiol Aging 1999; 20 (6): 597-603
55. Alexianu ME, Robbins E, Carswell S, et al. 1Alpha, 25 dihydroxyvitamin D3-dependent up-regulation of calciumbinding proteins in motoneuron cells. J Neurosci Res 1998; 51 (1): 58-66 (Pubitemid 28063148)
56. DeViragh PA, Haglid KG, CelioMR. Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. Proc Natl Acad Sci USA 1998; 86 (10): 3887-90
57. McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22 (4): 982-1001 (Pubitemid 351519955)
58. Wu CK, Thal L, Pizzo D, et al. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease. Exp Neurol 2005; 195 (2): 484-96 (Pubitemid 41297799)
59. Palop JJ, Jones B, Kekonius L, et al. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci USA 2003; 100 (16): 9572-7 (Pubitemid 37033969)
60. Dawson VL, Dawson TM. Nitric oxide actions in neurochemistry. Neurochem Int 1996; 29 (2): 97-110 (Pubitemid 126746194)
61. Garcion E, Nataf S, Berod A, et al. 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res 1997; 45 (2): 255-67 (Pubitemid 27170702)
62. Garcion E, Sindji L, Montero-Menei C, et al. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia 1998; 22 (3): 282-94 (Pubitemid 28159019)
63. Garcion E, Sindji L, Nataf S, et al. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol 2003; 105 (5): 438-48 (Pubitemid 36798839)
64. Naveilhan P,Neveu I, Baudet C, et al. 1,25-dihydroxyvitamin D-3 regulates the expression of the low-affinity neurotrophin receptor. Mol Brain Res 1996; 41 (1-2): 259-68 (Pubitemid 26288168)
65. Neveu I, Naveilhan P, Jehan F, et al. 1,25-Dihydroxyvitamin D-3 regulates the synthesis of nerve growth-factor in primary cultures of glial-cells. Mol Brain Res 1994; 24 (1-4): 70-6
66. Wion D, Macgrogan D, Neveu I, et al. 1,25-Dihydroxyvitamin- D3 is a potent inducer of nerve growth-factor synthesis. J Neurosci Res 1991; 28 (1): 110-4
67. Brown J, Bianco JI, McGrath JJ, et al. 1,25-Dihydroxyvitamin D-3 induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett 2003; 343 (2): 139-43 (Pubitemid 36577534)
68. Eyles D, Brown J, Mackay-Sim A, et al. Vitamin D-3 and brain development. Neurosci 2003; 118 (3): 641-53
69. Ko P, Burkert R, McGrath J, et al. Maternal vitamin D(3) deprivation and the regulation of apoptosis and cell cycle during rat brain development. Brain Res Dev Brain Res 2004; 153 (1): 61-8 (Pubitemid 39298877)
70. Feron F, Burne TH, Brown J, et al. Developmental Vitamin D3 deficiency alters the adult rat brain. Brain Res Bull 2005; 65 (2): 141-8 (Pubitemid 40348799)
71. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11 (5): 551-5 (Pubitemid 40691288)
72. Wang Y, Chiang YH, Su TP, et al. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology 2000; 39 (5): 873-80 (Pubitemid 30103691)
73. Yu J, Gattoni-Celli M, Zhu H, et al. Vitamin D3-enriched diet correlates with a decrease of amyloid plaques in the brain of AbetaPP Transgenic Mice. J Alzheimers Dis 2011; 25 (2): 295-307
74. Sonnenberg J, Luine V-N, Krey L-C, et al. 1,25-dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986; 118 (4): 1433-9 (Pubitemid 16078517)
75. Masoumi A, Goldenson B, Ghirmai S, et al. 1Alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis 2009; 17 (3): 703-17
76. Ito S, Ohtsuki S, Nezu Y, et al. 1a,25-Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid-b peptide( 1-40) from mouse brain across the blood-brain barrier [letter]. Fluids Barriers CNS 2011; 8: 20
77. Fantino B, Beauchet O, Savignat S, et al. Profile of French community-dwelling older adults supplemented with vitamin D: findings and lessons. Adv Ther 2011; 28 (6): 483-9
78. Annweiler C, Allali G, Allain P, et al. Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol 2009; 16 (10): 1083-9
79. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 2010; 170 (13): 1135-41
80. Annweiler C, Fantino B, Le Gall D, et al. Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. J Am Geriatr Soc 2011; 59 (1): 169-71
81. Buell JS, Dawson-Hughes B, Scott TM, et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74 (1): 18-26
82. Oudshoorn C, Mattace-Raso FU, Van Der Velde N, et al. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer's disease. Dementia Geriatr Cogn Disord 2008; 25 (6): 539-43 (Pubitemid 351957417)
83. Sato Y, Honda Y, Hayashida N, et al. Vitamin K deficiency and osteopenia in elderly women with Alzheimer's disease. Arch Phys Med Rehabil 2005; 86 (3): 576-81 (Pubitemid 40326644)
84. Sato Y, Asoh T, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 1998; 23 (6): 555-7 (Pubitemid 28529461)
85. Gezen-Ak D, Dursun E, Ertan T, et al. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med 2007; 212 (3): 275-82 (Pubitemid 47304994)
86. Bouillon R, Carmeliet G, Daci E, et al. Vitamin D metabolism and action. Osteoporos Int 1998; 8 Suppl. 2: S13-9
87. Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009; 84 (1): 35-43
88. Annweiler C, Beauchet O. Vitamin D-mentia: randomized clinical trials should be the next step. Neuroepidemiology 2011; 37: 249-58
89. Annweiler C, Fantino B, Parot-Schinkel E, et al. Alzheimer's Disease - Input of vitamin D with mEmantine Assay (AD-IDEA Trial): study protocol for a randomized controlled trial. Trials 2011; 12 (1): 230
90. Annweiler C, Schott AM, Rolland Y, et al. Dietary intake of vitamin D and cognition in older women: a large population- based study. Neurology 2010; 75 (20): 1810-6
91. University Hospital, Angers. Alzheimer's Disease - Input of Vitamin D with mEmantine Assay (AD-IDEA) [Clinical- Trials.gov identifier NCT01409694]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Dec 5]
92. Nowson C. Vitamin D status of Australians: impact of changes to mandatory fortification of margarine with vitamin D. Canberra (ACT): Australia and New Zealand Food Authority, 2001